Table 2 Multivariate analysis of anemia response

From: Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response

Variable

OR (95% CI)

Multivariate analysis, P

Treatment group

 

0.013

Thalidomide/prednisone

1

 

Thalidomide/prednisone/danazol

3.39 (1.29–8.89)

 

Gender

 

0.161

Male

1

 

Female

2.01 (0.76–5.31)

 

RBC transfusion dependent

 

0.03

≥6U/12W

1

 

<6U/12W

2.90 (1.11–7.61)

 

Palpable spleen length

 

0.225

LCM <5 cm

1

 

LCM ≥5 cm

1.82 (0.69–4.79)

 
  1. OR odds ratio, CI confidence interval, LCM left costal margin
Back to article page